Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study
Abstract Objectives To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT). Methods In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02509-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268700859432960 |
|---|---|
| author | Jun Shen Min Zhou Guangliang Zhu Yu Zhang Jinzhi Ma Dekui Li Lei Chen Kejun Qi Anjiang Wang Yang Jiang Zhiming Dai Xiaoming Li |
| author_facet | Jun Shen Min Zhou Guangliang Zhu Yu Zhang Jinzhi Ma Dekui Li Lei Chen Kejun Qi Anjiang Wang Yang Jiang Zhiming Dai Xiaoming Li |
| author_sort | Jun Shen |
| collection | DOAJ |
| description | Abstract Objectives To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT). Methods In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received dexmedetomidine (0.2–1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed. Results Doses ≥ 0.4 μg/kg (D2–D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4–D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2–D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays. Conclusions Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose. |
| format | Article |
| id | doaj-art-7bdfb31cfba740e78d4754fe74a8ff84 |
| institution | OA Journals |
| issn | 2047-783X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj-art-7bdfb31cfba740e78d4754fe74a8ff842025-08-20T01:53:23ZengBMCEuropean Journal of Medical Research2047-783X2025-04-013011710.1186/s40001-025-02509-3Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment studyJun Shen0Min Zhou1Guangliang Zhu2Yu Zhang3Jinzhi Ma4Dekui Li5Lei Chen6Kejun Qi7Anjiang Wang8Yang Jiang9Zhiming Dai10Xiaoming Li11Department of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeDepartment of Psychiatry, Lu’an Mental Health CenterDepartment of Psychiatry, Lu’an Mental Health CenterDepartment of Psychiatry, Lu’an Mental Health CenterDepartment of Psychiatry, Lu’an Mental Health CenterDepartment of Anesthesiology, The First People’s Hospital of XianyangDepartment of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational CollegeAbstract Objectives To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT). Methods In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1–D5; 42/group). Groups D1–D5 received dexmedetomidine (0.2–1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed. Results Doses ≥ 0.4 μg/kg (D2–D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4–D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2–D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays. Conclusions Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.https://doi.org/10.1186/s40001-025-02509-3DexmedetomidineModified electroconvulsive therapyAnesthesiaPreconditioningOptimal dose |
| spellingShingle | Jun Shen Min Zhou Guangliang Zhu Yu Zhang Jinzhi Ma Dekui Li Lei Chen Kejun Qi Anjiang Wang Yang Jiang Zhiming Dai Xiaoming Li Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study European Journal of Medical Research Dexmedetomidine Modified electroconvulsive therapy Anesthesia Preconditioning Optimal dose |
| title | Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study |
| title_full | Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study |
| title_fullStr | Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study |
| title_full_unstemmed | Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study |
| title_short | Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study |
| title_sort | dexmedetomidine for modified electroconvulsive therapy a dose optimized treatment study |
| topic | Dexmedetomidine Modified electroconvulsive therapy Anesthesia Preconditioning Optimal dose |
| url | https://doi.org/10.1186/s40001-025-02509-3 |
| work_keys_str_mv | AT junshen dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT minzhou dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT guangliangzhu dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT yuzhang dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT jinzhima dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT dekuili dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT leichen dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT kejunqi dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT anjiangwang dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT yangjiang dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT zhimingdai dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy AT xiaomingli dexmedetomidineformodifiedelectroconvulsivetherapyadoseoptimizedtreatmentstudy |